Inhibition of acid sphingomyelinase activity ameliorates endothelial dysfunction in db/db mice. Issue 4 (23rd April 2019)

• Record Type: Journal Article
• Authors: Jiang, Meng; Huang, Shanya; Duan, Wang; Liu, Qiaoshu; Lei, Minxiang
• Is Part Of: Bioscience reports. Volume 39:Issue 4(2019)
• Publication Date: 2019-04-23
• Subjects: acid sphingomyelinase -- ceramide -- diabetes -- endothelial dysfunction; Molecular biology -- Periodicals; Cytology -- Periodicals; 572.8
• DOI: 10.1042/BSR20182144
• Languages: English
• ISSNs: 0144-8463

Abstract

Abstract : Acid sphingomyelinase (aSMase) plays an important role in endothelial dysfunction. Here, we show that elevated aSMase activity and ceramide content were reduced by desipramine treatment in diabetic animals. The inhibitor of aSMase, desipramine, improved vascular dysfunction in db/db mice. High glucose (HG)-induced up-regulation of aSMase activity and ceramide levels were restored by treatment with aSMase siRNA or desipramine in endothelial cells. In addition, aSMase siRNA or desipramine treatment increased the release of nitric oxide (NO) and the phosphorylation of endothelial NO synthase (eNOS) in diabetic mouse aortas and aortic endothelial cells with HG. These results indicate that inhibition of aSMase/ceramide pathway improves endothelium-dependent vascular relaxation (EDR) largely through regulating the eNOS/NO pathway in diabetic animals.